In my opinion, successful Cruise 1 data will propel the stock to at least $15/share or higher. The naysayers refuse to accept the PRIME study data and the reduction in ESA usage due to SFP. SFP has been proven by four separate DSMB to be very safe and will be a blockbuster once Cruise 1 and Cruise 2 results are in. Calcitriol will also significantly enhance revenues and profits once its approved and in the marketplace. The Cruise 1 trial should be complete by the end of next week and I fully expect management will reach that goal.
I believe the company will be bought out by Baxter or some other major player after successful launch of SFP.